EA033323B1 - Кристаллические формы железной соли мальтола - Google Patents

Кристаллические формы железной соли мальтола

Info

Publication number
EA033323B1
EA033323B1 EA201790667A EA201790667A EA033323B1 EA 033323 B1 EA033323 B1 EA 033323B1 EA 201790667 A EA201790667 A EA 201790667A EA 201790667 A EA201790667 A EA 201790667A EA 033323 B1 EA033323 B1 EA 033323B1
Authority
EA
Eurasian Patent Office
Prior art keywords
crystalline forms
ferric maltol
maltol
ferric
anaemia
Prior art date
Application number
EA201790667A
Other languages
English (en)
Other versions
EA201790667A1 (ru
Inventor
Дэвид Пол Чайлдс
Original Assignee
ШИЛД ТиИкс (Юкей) ЛИМИТЕД
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52103522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA033323(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ШИЛД ТиИкс (Юкей) ЛИМИТЕД filed Critical ШИЛД ТиИкс (Юкей) ЛИМИТЕД
Publication of EA201790667A1 publication Critical patent/EA201790667A1/ru
Publication of EA033323B1 publication Critical patent/EA033323B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds
    • C07F15/025—Iron compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Предлагаются полиморфы железной соли мальтола. Такие формы могут быть пригодны для лечения дефицита железа с анемией или без нее, такого как железодефицитная анемия.
EA201790667A 2014-10-28 2015-10-23 Кристаллические формы железной соли мальтола EA033323B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1419174.6A GB2531742B (en) 2014-10-28 2014-10-28 Polymorphs of ferric maltol
PCT/EP2015/074653 WO2016066555A1 (en) 2014-10-28 2015-10-23 Crystalline forms of ferric maltol

Publications (2)

Publication Number Publication Date
EA201790667A1 EA201790667A1 (ru) 2017-08-31
EA033323B1 true EA033323B1 (ru) 2019-09-30

Family

ID=52103522

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790667A EA033323B1 (ru) 2014-10-28 2015-10-23 Кристаллические формы железной соли мальтола

Country Status (18)

Country Link
US (1) US9802973B2 (ru)
EP (1) EP3160951B1 (ru)
JP (2) JP6404358B2 (ru)
KR (1) KR102576930B1 (ru)
CN (1) CN107001310B (ru)
AU (1) AU2015340825B2 (ru)
CA (1) CA2944210C (ru)
CL (1) CL2017001030A1 (ru)
EA (1) EA033323B1 (ru)
ES (1) ES2661944T3 (ru)
GB (1) GB2531742B (ru)
IL (1) IL251863A0 (ru)
MX (1) MX370730B (ru)
PL (1) PL3160951T3 (ru)
SA (1) SA517381406B1 (ru)
SG (1) SG11201702639RA (ru)
WO (1) WO2016066555A1 (ru)
ZA (1) ZA201702136B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531742B (en) 2014-10-28 2016-10-05 Iron Therapeutics Holdings Ag Polymorphs of ferric maltol
CN112574158B (zh) * 2020-12-29 2022-08-02 南京百泽医药科技有限公司 一种麦芽酚铁晶型ii及其制备方法
IT202100018578A1 (it) 2021-07-14 2023-01-14 Indena Spa Dispersione amorfa di maltolo ferrico e relativo processo di preparazione
AU2022349859A1 (en) * 2021-09-21 2024-05-02 Apicore Pharmaceuticals Private Limited An improved process for the preparation of ferric maltol

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0159917A2 (en) * 1984-04-19 1985-10-30 National Research Development Corporation Pharmaceutical composition containing a hydroxypyrone-iron complex
WO2003097627A1 (en) * 2002-05-18 2003-11-27 Vitra Pharmaceuticals Limited Method of forming iron hydroxypyrone compounds
WO2012101442A1 (en) * 2011-01-27 2012-08-02 Iron Therapeutics Holdings Ag Process

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE37534E1 (en) 1982-10-22 2002-01-29 Btg International Limited Pharmaceutical compositions
GB2128998B (en) * 1982-10-22 1986-07-16 Nat Res Dev Pharmaceutical compositions of iron complexes of 3 hydroxy-4-pyrone
WO2014165607A2 (en) 2013-04-02 2014-10-09 Stealth Peptides International, Inc. Aromatic-cationic peptide formulations, compositions and methods of use
GB2531742B (en) 2014-10-28 2016-10-05 Iron Therapeutics Holdings Ag Polymorphs of ferric maltol

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0159917A2 (en) * 1984-04-19 1985-10-30 National Research Development Corporation Pharmaceutical composition containing a hydroxypyrone-iron complex
WO2003097627A1 (en) * 2002-05-18 2003-11-27 Vitra Pharmaceuticals Limited Method of forming iron hydroxypyrone compounds
WO2012101442A1 (en) * 2011-01-27 2012-08-02 Iron Therapeutics Holdings Ag Process

Also Published As

Publication number Publication date
US9802973B2 (en) 2017-10-31
GB2531742B (en) 2016-10-05
PL3160951T3 (pl) 2018-07-31
GB201419174D0 (en) 2014-12-10
ZA201702136B (en) 2018-11-28
JP6678711B2 (ja) 2020-04-08
JP6404358B2 (ja) 2018-10-10
CN107001310A (zh) 2017-08-01
WO2016066555A1 (en) 2016-05-06
SA517381406B1 (ar) 2021-03-15
EP3160951A1 (en) 2017-05-03
AU2015340825A1 (en) 2016-08-25
KR20170071446A (ko) 2017-06-23
BR112017008903A2 (pt) 2017-12-19
MX2017005413A (es) 2017-10-04
US20170260222A1 (en) 2017-09-14
EP3160951B1 (en) 2017-12-06
JP2018197268A (ja) 2018-12-13
SG11201702639RA (en) 2017-05-30
CA2944210A1 (en) 2016-05-06
IL251863A0 (en) 2017-06-29
GB2531742A (en) 2016-05-04
MX370730B (es) 2019-12-20
CN107001310B (zh) 2020-05-22
CL2017001030A1 (es) 2018-01-19
CA2944210C (en) 2017-06-20
EA201790667A1 (ru) 2017-08-31
AU2015340825B2 (en) 2016-11-24
ES2661944T3 (es) 2018-04-04
JP2017535510A (ja) 2017-11-30
KR102576930B1 (ko) 2023-09-12

Similar Documents

Publication Publication Date Title
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
PH12016501763A1 (en) Multispecific antibodies
HK1254358A1 (zh) 用於治療突觸核蛋白病的藥劑、用途和方法
PH12016502586A1 (en) Lipid comprising docosapentaenoic acid
MX2016016881A (es) Anticuerpos que se unen a axl.
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
MX2017000363A (es) Inhibicion de la via de notch.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2015013686A (es) Composiciones y metodos para potenciar la estabilidad microbiana.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
HK1223923A1 (zh) 用於治療癌症的作為 突變體抑制劑的 -或 -二氨基嘧啶化合物
PH12015502665A1 (en) Improvements in or relating to organic compounds
PH12017501071A1 (en) Dihydropyrimidin-2-one compounds and medical use thereof
PH12017501864A1 (en) Compositions and methods for treating autism
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
MX2017005249A (es) Compuestos para usarse en el tratamiento antihelmintico.
GB201510785D0 (en) Compostable Laminates
EA033323B1 (ru) Кристаллические формы железной соли мальтола
MX2017001047A (es) Compuestos para usar en el tratamiento antihelmintico.
IN2014CH00151A (ru)
MX2016015507A (es) Desaromatizacion oxidativa de berbinas.
ZA201608404B (en) Enzyme treatment composition
GB201605341D0 (en) Modified microorganisms
GB201605378D0 (en) Modified microorganisms

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG TJ TM